Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Added a study site: Cali, Valle del Cauca Department, Colombia, 760023, and removed Santiago de Cali, Valle del Cauca Department, Colombia, 760023 from the locations list.
    Difference
    0.2%
    Check dated 2025-10-30T12:00:20.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    39 days ago
    Change Detected
    Summary
    Update to a newer revision identifier (v3.2.0) replaces the older v3.0.2.
    Difference
    0.0%
    Check dated 2025-10-01T05:55:53.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Update: version revision changed from v3.0.2 to v3.1.0.
    Difference
    0.0%
    Check dated 2025-09-30T03:48:29.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Removed content on Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, and Substandard Drugs, narrowing the page’s coverage of medical/pharmaceutical topics.
    Difference
    0.2%
    Check dated 2025-09-22T23:45:53.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    Localization update: place names now use the Tatar-language form ‘Respublika’ (e.g., Kazan’, Tatarstan, Respublika, Russia, 420029) instead of ‘Tatarstan Republic’; page revision bumped to v3.0.2, with a minor removal of the Back to Top element.
    Difference
    0.2%
    Check dated 2025-09-15T19:30:31.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-08T15:05:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.